Track topics on Twitter Track topics that are important to you
BOSTON — Dexamethasone implant, ranibizumab injections or a combination of the two each yielded no statistically significant difference in visual acuity or central retinal thickness changes in treatment of central retinal vein occlusion, according to a speaker here.“The two approaches that we have currently for treatment [of CRVO] include the dexamethasone implant and the anti-VEGF agents,” Victor H. Gonzalez, MD, said at the American Society of Retina Specialists meeting, where he gave an interim analysis of the ORION study. “Because the etiology of CRVO macular edema finds its basis in both inflammatory and vascular changes, we found it of interest to see if a multimodal approach may help in the treatment of this condition.”
Original Article: Treatment arms for CRVO yield no difference in visual acuity resultsNEXT ARTICLE
Vascular relates to blood vessels (Oxford Medical Dictionary) and can be used to describe the supply of blood, a disease affecting the blood vessels or molecules associated with these structures. For example, <!--LGfEGNT2Lhm-->atherosclerosis ...